New products to be distributed through
Khiron's new wholly-owned subsidiary Pharmadrug Production
GmbH
- Khiron introduces new THC-dominant full-spectrum extract
KHIRIOX 25/1, and non-irradiated flower varieties KHIRON Gelato
19/1 and KHIRON Caramel 5/7 in the European market
- Khiron's expanded medical product portfolio in Europe will provide a broader patient base
with in-demand products
TORONTO, Sept. 1,
2022 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or
the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical
cannabis throughout Europe and
Latin America, announces its new
medical product portfolio in Europe. The new products, which are already
being promoted to prescribers, pharmacies, and patients, will be
exclusively distributed through Khiron's wholly-owned Pharmadrug
Production GmbH and will be available to pharmacies and patients in
Germany and the UK in the coming
weeks.
The THC-dominant full-spectrum extract KHIRIOX 25/1 combines the
medicinal properties and areas of application of the established
THC isolate formulations (dronabinol) with the specific advantages
of a full spectrum extract. This new product is based on Khiron's
current top selling and effective extract formulation in
Latin America.
Khiron will also introduce non-irradiated flower varieties
KHIRON Gelato 19/1 and KHIRON Caramel 5/7. These varieties are very
popular in California among
consumers and patients and are in very high demand in Europe.
Franziska Katterbach, President of Khiron Europe, stated: "With
the acquisition of Pharmadrug, Khiron is now able to completely
control the value chain in Europe,
and we can introduce new products that are in high demand in the
European market with potential higher margins. With these new
additions to our medical portfolio, Khiron Europe now covers the
entire spectrum of chemotypes, therapies and routes of
administration in the interest of all our European prescribers and
patients. With our new medical products, we offer patients what
they want and need. Especially our new flower varieties Gelato and
Caramel illustrate that medicine does not have to be bitter."
About Khiron Life Sciences
Corp.
Khiron is a leading global medical cannabis company with core
operations in Latin America and
Europe. Leveraging wholly-owned
medical health clinics and proprietary telemedicine platforms,
Khiron combines a patient-oriented approach, physician education
programs, scientific expertise, product innovation, and focus on
creating access to drive prescriptions and brand loyalty with
patients worldwide. The Company has a sales presence in
Colombia, Germany, the United
Kingdom, Peru, and
Brazil and is positioned to
commence sales in Mexico. The
Company is led by its co-founder and Chief Executive Officer,
Alvaro Torres, together with an
experienced and diverse executive team and board of directors.
Visit Khiron online at https://investors.khiron.ca.
LinkedIn
About Pharmadrug Production
GmbH
Pharmadrug GmbH has been active worldwide for more than 30 years
as a manufacturer and wholesaler of medicinal products and active
pharmaceutical ingredients, as well as holding a licence to handle
narcotics in Germany. Pharmadrug
GmbH is EU-GMP (Good Manufacturing Practice) and EU-GDP (Good
Distribution Practice) certified, fulfilling the European
guidelines for the highest quality standards.
Cautionary Statement Regarding
Forward-Looking Information
This press release may contain "forward-looking information"
within the meaning of applicable securities legislation. All
information contained herein that is not historical in nature
constitutes forward-looking information. Forward-looking
information contained in this news release may include statements
pertaining to the expected synergies and benefits to the Company
from the acquisition of the Target as well as statements as to
business strategy. Forward-looking information and statements
contained in this news release reflect management's current beliefs
and is based on information currently available and on assumptions
that management believes to be reasonable. These assumptions
include, but are not limited to, the expected benefits to be
realized by Khiron's business as a result of the acquisition of the
Target, and assumptions regarding market opportunities in the
jurisdictions in which the Company operates and where it seeks to
operate.
Although management believes that its expectations and
assumptions to be reasonable, forward-looking information is always
subject to known and unknown risks, uncertainties and other
factors, many of which are beyond the control of management, that
may cause actual results to differ materially from those expressed
or implied in such forward-looking information. Such risks and
uncertainties include but are not limited to the following: general
economic conditions, adverse conditions in capital markets,
political uncertainties, counterparty risk, failing to obtain
required regulatory requirements and approvals, failure to maintain
required permits and licences, business integration risks, as well
as those other risk factors discussed in Khiron's most recent
annual information form which is available on Khiron's SEDAR
profile at www.sedar.com.
As a result of the foregoing and other risks and uncertainties,
readers are cautioned not to place undue reliance on
forward-looking information contained in this press release.
Readers are further cautioned that the foregoing risks and
uncertainties is not exhaustive, and there may be other risks and
uncertainties, presently unknown to management of the Company, that
may cause actual results to differ materially from those expressed
or implied in forward-looking statements contained in this press
release. The forward-looking information contained in this press
release is expressly qualified by this cautionary statement. Khiron
disclaims any intention to update or revise any forward-looking
information disclosed herein, whether as a result of new
information, future events or otherwise, except as required by
law.
NEITHER THE TSX VENTURE EXCHANGE, NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VEMTIRE EXCHANGE), ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS PRESS RELEASE.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-the-global-leader-in-medical-cannabis-launches-new-cannabis-products-in-europe-including-stellar-genetics-from-california-301616441.html
SOURCE Khiron Life Sciences Corp.